Regarding “Apolipoprotein E and Alzheimer’s Disease: the influence of apoE on amyloid β and other amyloidogenic proteins” (J. Lipid Res. 58: 824–836):
The conflict of interest statement was inadvertently omitted. David M. Holtzman (D.M.H.) is an inventor on a patent filed by Washington University of the topic of anti-apoE antibodies that was licensed by Denali. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. consults for Genentech, AbbVie, Eli Lilly, Proclara, and Denali. Washington University receives research grants to the laboratory of D.M.H. from C2N Diagnostics, Eli Lilly, AbbVie, and Denali.